ReCode Therapeutics

If you're at #JPM2025, check out the AMM panel "mRNA Therapies: Advancing and Scaling the Future of Medicine." The event kicks off at 9:00 am PST tomorrow. We will share a live stream here for those not in attendance. The panel will discuss mRNA's efficacy, commercial viability, and targeted neo-antigen therapies for oncology, autoimmune diseases, infectious diseases, rare diseases, and other conditions. A special shout out to our participants: Ipsita Smolinski with Capitol Street, Ariel Kantor, PhD with ReCode Therapeutics, Joe Payne with Arcturus Therapeutics, Gilles Besin with Orbital Therapeutics, Sadik Kassim with Danaher Corporation, and Guillaume Pfefer with Sail Biomedicines.

ReCode Therapeutics proudly stands with the Biotech CEO Sisterhood.

Ariel Kantor, PhD, our Senior Vice President of Business and Corporate Development, will moderate a panel hosted by the Alliance for mRNA Medicines at the J.P. Morgan Healthcare Conference on January 15, 2025. This panel will convene industry leaders to discuss the transformative potential of mRNA medicines and their impact on global health. As proud members of the AMM, we are pleased to contribute to its mission of advancing mRNA therapeutics for the benefit of patients, public health, and society. #mRNA  #JPM2025

ReCode Therapeutics will be at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16. Connect with members our leadership team onsite: — Shehnaaz Suliman, M.D., CEO — David Lockhart, CSO — Ariel Kantor, PhD, SVP of Business and Corporate Development — Erica Jefferson, SVP of Corporate Affairs — Eneda Hoxha, VP, Intellectual Property and Business Development Investors looking to schedule a meeting to learn more about what ReCode is doing to transform patient care through precision genetic medicine for diseases like cystic fibrosis and primary ciliary dyskensia, please visit the following link: https://lnkd.in/gEsWCVhj Companies interested in partnering opportunities please email: partnering@recodetx.com. #JPM25 #JPM2025

Join ReCode Therapeutics’ CEO, Shehnaaz Suliman, M.D., as she takes the stage during Fierce Biotech JPM Week for an exclusive panel discussion: “Cell & Gene Therapy: Challenges, Trends and Technologies” Be part of the conversation as Shehnaaz and an expert panel of industry leaders tackle some of the most critical issues shaping the future of gene therapy, including: — Overcoming manufacturing bottlenecks for scalability  — Regulatory complexities impacting global clinical adoption  — Unlocking platform technologies to address broader disease states Gain insights from biotech’s brightest minds and see how companies like ReCode are driving progress in precision genetic medicine. For more info, visit https://lnkd.in/gXZsPndV #JPM2025

Reflecting on 2024, we at ReCode Therapeutics recognize the significant progress made in advancing genetic medicines. This year, our milestones included the development of the RCT2100 and RCT1100 clinical studies, showcasing the potential of our selective organ targeting (SORT) lipid nanoparticle (LNP) platform to treat conditions like Primary Ciliary Dyskinesia (PCD) and Cystic Fibrosis. Our team's dedication has driven scientific advancements and reinforced our core mission: to power the future of genetic medicines with precision delivery. As 2024 comes to a close, we extend our gratitude to our dedicated team, valued partners, and the patient communities who drive our mission forward. We look ahead to 2025 with renewed energy, ready to continue our pursuit of treatments for all. #GeneticMedicine #CysticFibrosis #PCD #TeamReCode

Congratulations to one of our co-founders, Daniel Siegwart, for being named a fellow of the National Academy of Investors. Dr. Siegwart joins other academic researchers dedicated to enhancing the visibility of technology and innovations developed in an academic setting and increasing the public's awareness of the role investors play in bringing novel technologies and therapies to people around the world. His groundbreaking work has shown that ReCode's proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform is designed to allow highly precise and targeted delivery of genetic medicine cargo such as mRNA, siRNA and gene correction modalities.

Over 80% of people surveyed by the PCD Foundation have a positive view of clinical trials. Participating in a #ClinicalTrial may help to advance science and help others with the same condition in the future. For more information about PCD and a clinical study investigating a potential new treatment in the UK, visit https://lnkd.in/gAVUdG-p #clinicaltrials #PrimaryCiliaryDyskinesia #PCD

Did you know it’s estimated that over 50,000 people have undiagnosed primary ciliary dyskinesia (PCD)? This rare genetic disorder often goes unnoticed until adulthood, leading to a decline in lung function without early intervention. The diagnosis process can be complex and challenging - which is why raising awareness of PCD is critical. For more information about PCD and a clinical study investigating a potential new treatment in the UK, visit https://lnkd.in/gAVUdG-p #PCD #PrimaryCiliaryDyskinesia #ClinicalStudies

Quick Facts About Primary Ciliary Dyskinesia (PCD) 🫁 Did you know that Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that disrupts the tiny, hair-like structures in your airways called cilia? These hardworking cilia are responsible for clearing mucus from your lungs, but when they don’t function properly, it leads to chronic respiratory infections, sinus problems, and potential lung damage over time. PCD is often caused by mutations in genes like DNAI1, which affect how cilia move and function. Our RCT1100 clinical study is investigating a treatment designed to restore normal ciliary function in the lungs—tackling the root cause of PCD. Be part of the future of PCD treatment. Learn more about how you can get involved in our study: https://lnkd.in/gupUm-8U